Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
November is Lung Cancer Awareness Month.
People whose cancer was detected via regular CT scans had an 81% lung cancer-specific survival rate at 20 years.
A new type of targeted immunotherapy drug, tarlatamab shrank tumors in about 1 in 3 people with small-cell lung cancer.
Annual screening is now recommended for current and former smokers ages 50 to 80, regardless of when they quit.
Researchers found a new gene, ZFP36L1, that hasn’t been studied in association with small-cell lung cancer and the protein LSD1.
Regular screening can detect lung cancer early, when it’s easier to treat.
Human trial opens after experimental drug slows tumor growth suppression in mice.
Personalized risk assessment identified 9% more lung cancer cases for screening compared with current U.S. guidelines.
Providers who treat smokers with lung cancer should offer support to help them quit.
Breathing and pain management have gotten better since I last wrote, so now I can come up for air and write with a little more hope.
New patient/caregiver resource from the National Comprehensive Cancer Network focuses on small cell lung cancer, an aggressive cancer.
Imfinzi plus chemotherapy led to a modest but significant improvement in overall survival.
This issue explores various treatment options for small-cell lung cancer and ways to manage side effects.
Chemotherapy, immunotherapy and radiation are the mainstays of SCLC treatment.
After a small-cell lung cancer (SCLC) diagnosis, you need education, support, access to care and help with finances.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.